Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

Timeline

Start

2025-11-18

Primary completion

2027-06

Completion

2027-06

Drugs

Indications